Cardiovascular Systems, Inc. to Participate in 8th Annual Intellisight Investor Conference on August 14

Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease.

Metadata
Provider: 
Business Wire, Inc.
Retrieved on: 
Wednesday, August 7, 2019
Information
Tags: 
Manufacturing, Other Health, Other Technology, Pharmaceutical, Finance, Medical devices, Professional services, Technology, Cardiology, Biotechnology, Surgery, Health, Engineering, Cardiovascular system, Circulatory system, Medical specialties, Interventional radiology, Atherectomy, Vascular surgery, RTT, Artery, Coronary artery disease
Geotags: 
United States, Minnesota
⚠generated by AI ↴
Summary
Key Points: 
  • Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease.
  • The U.S. FDA granted 510(k) clearance for the use of the Diamondback Orbital Atherectomy System in peripheral arteries in August 2007.
  • In October 2013, the company received FDA approval for the use of the Diamondback Orbital Atherectomy System in coronary arteries.
  • In March 2017, the company received PMDA approval in Japan for the Diamondback 360 Coronary OAS Micro Crown and reimbursement approval effective February 2018.


Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that management will present and host investor meetings at the 8th Annual Intellisight Conference in Minneapolis, Minn. on Wednesday, August 14th at 7:30 a.m. Central Time.

Interested parties can view the Company’s live presentation at http://www.wsw.com/webcast/intel19/.

About Cardiovascular Systems, Inc.

Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The company’s OAS treat calcified and fibrotic plaque in arterial vessels throughout the leg and heart in a few minutes of treatment time, and address many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives. The U.S. FDA granted 510(k) clearance for the use of the Diamondback Orbital Atherectomy System in peripheral arteries in August 2007. In October 2013, the company received FDA approval for the use of the Diamondback Orbital Atherectomy System in coronary arteries. The Stealth 360® Peripheral Orbital Atherectomy System (OAS) received CE Mark in October 2014. In March 2017, the company received PMDA approval in Japan for the Diamondback 360® Coronary OAS Micro Crown and reimbursement approval effective February 2018. Over 470,000 of CSI’s devices have been sold to leading institutions worldwide. For more information, visit the company’s website at www.csi360.com.

Copyright: 
Copyright Business Wire 2019